search
Back to results

Physiologic Volume and Atrophy of Brain and Spinal Cord Measured by Magnetic Resonance Imaging

Primary Purpose

Cognitive Change, Atrophy Brain, Atrophy; Spinal Cord

Status
Unknown status
Phase
Not Applicable
Locations
Czechia
Study Type
Interventional
Intervention
Magnetic resonance imaging
Sponsored by
Dana Horakova
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Cognitive Change focused on measuring Multiple Sclerosis, Spinal Cord Atrophy

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Each participant must provide informed consent in accordance with local regulations
  2. Age 18-60 years.

Exclusion Criteria:

  1. Not able to undergo MRI examination
  2. Not able to be examined 4 times, i.e. M 0, 12, 24, 36 during the next 3 years
  3. Pregnancy at the time of enrollment into the study
  4. Other disease or medical condition that can influence the volume of brain or spinal cord

Sites / Locations

  • Dpt of Neurology, Charles University and General University Hospital in Prague

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

MRI and Neuropsychologic testing

Arm Description

102 healthy controls will be examined by magnetic resonance imaging (MRI) of brain, spinal and thoracic cord at month 0, 12, 24 and 36. 102 healthy controls will be examined by neuropsychological and walking testing designed for patients with multiple sclerosis at month 0, 12, 24 and 36.

Outcomes

Primary Outcome Measures

Measure Spinal Cord Volume Change at 12 months during 3 years follow-up in Healthy Controls
Evaluation of Magnetic Resonance Imaging from each visit
Measure Spinal Cord Atrophy Change at 12 months during 3 years follow-up in Healthy Controls
Evaluation of Magnetic Resonance Imaging from each visit

Secondary Outcome Measures

Measure Whole Brain Volume and Atrophy at 12 months during 3 years follow-up in Healthy Controls
Evaluation of Magnetic Resonance Imaging from each visit
Measure Regional Brain Volumes and Atrophies at 12 months during 3 years follow-up in Healthy Controls
Evaluation of Magnetic Resonance Imaging from each visit

Full Information

First Posted
September 17, 2018
Last Updated
July 26, 2020
Sponsor
Dana Horakova
search

1. Study Identification

Unique Protocol Identification Number
NCT03706118
Brief Title
Physiologic Volume and Atrophy of Brain and Spinal Cord Measured by Magnetic Resonance Imaging
Official Title
Physiologic Interindividual Variability of Volume and Atrophy in Central Nervous System Structures With Focus on Spinal Cord as Measured by Quantitative Magnetic Resonance Imaging.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 15, 2018 (Actual)
Primary Completion Date
September 14, 2018 (Actual)
Study Completion Date
November 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dana Horakova

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Spinal cord (SC) involvement is prevalent in multiple sclerosis (MS) and contributes importantly to disease progression. To be able reliably evaluate spinal cord volume and its changes in MS patients we need to understand variability of these parameters in sex and age matched healthy controls (HC). To date, no generally available data about these parameters in HC are available. The objective of this study is to investigate age and sex matched HC by MRI to get the basic set of the data representing both cross sectional values and its longitudinal changes. The present study will also investigate different strategies how to normalize the absolute spinal cord and brain volume data, what is a relationship between spinal cord volume and brain volume and what is the best protocol to be used in a routine clinical practice.
Detailed Description
Multiple sclerosis (MS) is a chronic immune-mediated inflammatory and neurodegenerative disease that affects central nervous system. Magnetic resonance imaging (MRI) is the main paraclinical examination used to monitor disease activity and response to treatment. However, there is only limited correlation between the clinical symptoms and findings seen on the conventional MRI - a phenomena called clinical-radiological paradox. Measuring whole and regional brain atrophy provides additional information to MRI and seems to correlate better with clinical course and prognosis. In the last two decades, brain atrophy in MS has been exten sively studied, cut-offs for brain volume loss over time has been established and it is likely that it will become an important outcome measure in both clinical studies and routine practice. Compared to brain atrophy, spinal cord (SC) atrophy and its relation to MS-related disability has been given less attention. This is partly due to technical challenges such as inhomogeneous magnetic field in this region, small physical dimensions of SC and artefacts caused by motion of the SC within the spinal canal together with the flow of cerebrospinal fluid and periodic motion due to respiratory and cardiac cycles. Moreover, focal spinal cord MS lesions may cause both swelling and shrinking of SC that influence its absolute volume, resulting in problems with interpretation of absolute SC volume in MS. Despite all these challenges, it is possible to identify SC lesions and reliably measure SC volume, but there is no "gold standard" (standardized) software for SC volume measurement and no agreement on the SC level (segments) that is most suitable for SC volume loss measurement. During 2016 we have developed an in-house semiautomatic pipeline for measurement of cervical spinal cord volume that is a part of Scanview program. The segmentation is performed on T2-weighted images. In the first step, a marker is manually placed in a center of an intervertebral disc C3-4 (sagittal plane). Subsequently a cord straightening (manual rotation of the cord to achieve a perpendicular orientation of spinal cord to dorsal part of C3 vertebral body), that enable to reduce partial volume due to the cord orientation. After this centering and straightening,transformation matrix is saved and all subsequent steps are fully automatized. These steps include: 1. Sub-pixel division, 2. Reversing the contrast of T2-weighted images and smoothing by applying a set of median, Gaussian and edge-enhancing filters and 4. Cubic spline interpolation to find a curve that represents a border of a spinal cord with highest probability. Finally, a sum of mean areas of 21 1-mm slices is calculated (1 center slice fixed at center of a intervertebral disc C3-4 and 2 x 10 slices in cranial and caudal direction. Using this new software we have assessed 1,036 MS patients during 2016 and 2017. The intra- and inter-rater variability of SC volume assessment was done by using the intraclass correlation coefficient (ICC) with a two-way mixed absolute agreement and single-measures design. The analysis confirmed very good consistency (> 98%) of the method. The preliminary results showed a significant correlation between spinal cord volume and different clinical phenotypes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognitive Change, Atrophy Brain, Atrophy; Spinal Cord, Multiple Sclerosis
Keywords
Multiple Sclerosis, Spinal Cord Atrophy

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective, longitudinal, monocentric, interventional study
Masking
None (Open Label)
Allocation
N/A
Enrollment
102 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MRI and Neuropsychologic testing
Arm Type
Experimental
Arm Description
102 healthy controls will be examined by magnetic resonance imaging (MRI) of brain, spinal and thoracic cord at month 0, 12, 24 and 36. 102 healthy controls will be examined by neuropsychological and walking testing designed for patients with multiple sclerosis at month 0, 12, 24 and 36.
Intervention Type
Other
Intervention Name(s)
Magnetic resonance imaging
Intervention Description
At month 0, 12, 24 and 36 participants will be examined by quantitative magnetic resonance imaging of brain, cervical and part of thoracic spine.
Primary Outcome Measure Information:
Title
Measure Spinal Cord Volume Change at 12 months during 3 years follow-up in Healthy Controls
Description
Evaluation of Magnetic Resonance Imaging from each visit
Time Frame
Baseline, 12, 24, 36 months
Title
Measure Spinal Cord Atrophy Change at 12 months during 3 years follow-up in Healthy Controls
Description
Evaluation of Magnetic Resonance Imaging from each visit
Time Frame
Baseline, 12, 24, 36 months
Secondary Outcome Measure Information:
Title
Measure Whole Brain Volume and Atrophy at 12 months during 3 years follow-up in Healthy Controls
Description
Evaluation of Magnetic Resonance Imaging from each visit
Time Frame
Baseline, 12, 24, 36 months
Title
Measure Regional Brain Volumes and Atrophies at 12 months during 3 years follow-up in Healthy Controls
Description
Evaluation of Magnetic Resonance Imaging from each visit
Time Frame
Baseline, 12, 24, 36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Each participant must provide informed consent in accordance with local regulations Age 18-60 years. Exclusion Criteria: Not able to undergo MRI examination Not able to be examined 4 times, i.e. M 0, 12, 24, 36 during the next 3 years Pregnancy at the time of enrollment into the study Other disease or medical condition that can influence the volume of brain or spinal cord
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dana Horakova, MD, PhD
Organizational Affiliation
Dpt of Neurology, Charles University and General University Hospital in Prague
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dpt of Neurology, Charles University and General University Hospital in Prague
City
Prague
ZIP/Postal Code
12000
Country
Czechia

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35561554
Citation
Vaneckova M, Piredda GF, Andelova M, Krasensky J, Uher T, Srpova B, Havrdova EK, Vodehnalova K, Horakova D, Hilbert T, Marechal B, Fartaria MJ, Ravano V, Kober T. Periventricular gradient of T1 tissue alterations in multiple sclerosis. Neuroimage Clin. 2022;34:103009. doi: 10.1016/j.nicl.2022.103009. Epub 2022 Apr 16.
Results Reference
derived

Learn more about this trial

Physiologic Volume and Atrophy of Brain and Spinal Cord Measured by Magnetic Resonance Imaging

We'll reach out to this number within 24 hrs